In this video, Xinxin Wang, PhD, Gracell Biotechnologies, San Diego, CA, and Martina Sersch, MD, Gracell Biotechnologies, San Diego, CA, discuss the production of universal allogeneic CAR-T products and challenges faced with this process. Dr Wang mentions the challenge of graft-versus-host disease (GvHD) and graft rejection, and strategies to overcome this. Dr Wang then highlights methods of maximizing expansion and efficacy of novel universal CAR-T products. To conclude, Dr Sersch highlights the clinical importance and uniqueness of the allogeneic TruUCAR™ GC502 product and its application to the treatment of hematological malignancies. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.